Dasabuvir sodium monohydrateProduct ingredient for Dasabuvir
- Name
- Dasabuvir sodium monohydrate
- Drug Entry
- Dasabuvir
Dasabuvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients 8. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Dasabuvir. Dasabuvir is a non-nucleoside NS5B inhibitor which binds to the palm domain of NS5B and induces a conformational change which renders the polymerase unable to elongate viral RNA Label. The binding sites for non-nucleoside NS5B inhibitors are poorly conserved across HCV genotypes leading to the restriction of Dasabuvir's use to genotype 1 only.
In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Dasabuvir as first line therapy in combination with Ombitasvir, Paritaprevir, and Ritonavir for genotype 1b and with Ribavirin for genotype 1a of Hepatitis C 8. Dasabuvir, Ombitasvir, Paritaprevir, Ritonavir, and Ribavirin are used with the intent to cure, or achieve a sustained virologic response (SVR), after 12 weeks of therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality 7.
Dasabuvir is available as a fixed dose combination product with Ombitasvir, Paritaprevir, and Ritonavir (tradename Viekira Pak) used for the treatment of chronic Hepatitis C. Approved in December 2014 by the FDA, Viekira Pak is indicated for the treatment of HCV genotype 1a with Ribavirin or genotype 1b without Ribavirin Label. When combined together, Dasabuvir Ombitasvir, Paritaprevir, and Ritonavir as the combination product Viekira Pak have been shown to achieve a SVR of 100% for genotype 1b and 89% or 95% for genotype 1a after 12 weeks or 24 weeks of treatment including Ribavirin.
- Accession Number
- DBSALT002711
- Structure
- Synonyms
- Not Available
- UNII
- OG6D40M62L
- CAS Number
- 1456607-55-8
- Weight
- Average: 533.57
Monoisotopic: 533.15965109 - Chemical Formula
- C26H28N3NaO6S
- InChI Key
- SJHKKWUESHNTBB-UHFFFAOYSA-M
- InChI
- InChI=1S/C26H27N3O5S.Na.H2O/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18;;/h6-15,28H,1-5H3,(H,27,30,31);;1H2/q;+1;/p-1
- IUPAC Name
- sodium 3-[3-tert-butyl-5-(6-methanesulfonamidonaphthalen-2-yl)-4-methoxyphenyl]-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-1-ide hydrate
- SMILES
- O.[Na+].COC1=C(C=C(C=C1C(C)(C)C)N1C=CC(=O)[N-]C1=O)C1=CC2=C(C=C1)C=C(NS(C)(=O)=O)C=C2
- External Links
- ChemSpider
- 34992812
- ChEMBL
- CHEMBL3544985
- Predicted Properties
Property Value Source Water Solubility 0.00119 mg/mL ALOGPS logP 4.52 ALOGPS logP 3.42 Chemaxon logS -5.6 ALOGPS pKa (Strongest Acidic) 9.09 Chemaxon pKa (Strongest Basic) -4.8 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 102.01 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 133.24 m3·mol-1 Chemaxon Polarizability 52.82 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon